Cubist Systematic Strategies, LLC Glycomimetics Inc Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $126,984 - $173,795	49,798 New	49,798 $149,000
Q1 2023 May 15, 2023	SELL	$1.25 - $4.05 $4,197 - $13,599	-3,358 Reduced 6.95%	44,939 $56,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $27,529 - $146,339	48,297 New	48,297 $146,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $58,104 - $85,542	-26,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $29,873 - $43,622	10,337 Added 62.41%	26,900 $81,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $44,554 - $70,227	16,563 New	16,563 $62,000
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $43,442 - $75,447	-5,129 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $70,267 - $87,808	5,129 New	5,129 $74,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $48,820 - $64,037	-3,337 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $53,592 - $84,592	3,337 New	3,337 $54,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.